Published in J Natl Cancer Inst on December 05, 1990
ERBB2 amplification in breast cancer analyzed by fluorescence in situ hybridization. Proc Natl Acad Sci U S A (1992) 3.25
Elimination of extrachromosomally amplified MYC genes from human tumor cells reduces their tumorigenicity. Proc Natl Acad Sci U S A (1992) 1.27
Double minute chromosomes carrying the human multidrug resistance 1 and 2 genes are generated from the dimerization of submicroscopic circular DNAs in colchicine-selected KB carcinoma cells. Mol Biol Cell (1992) 1.12
Chromosomal and extrachromosomal instability of the cyclin D2 gene is induced by Myc overexpression. Neoplasia (1999) 0.97
Isolation and structural analysis of a 1.2-megabase N-myc amplicon from a human neuroblastoma. Mol Cell Biol (1992) 0.95
Gemcitabine eliminates double minute chromosomes from human ovarian cancer cells. PLoS One (2013) 0.94
Molecular structure and evolution of double-minute chromosomes in methotrexate-resistant cultured mouse cells. Mol Cell Biol (1992) 0.83
De novo-generated small palindromes are characteristic of amplicon boundary junction of double minutes. Int J Cancer (2013) 0.80
Resolution of DNA fragments from 23 kilobases to 6 megabases by biphasic linear pulse ramping. Nucleic Acids Res (1992) 0.79
Novel functional MAR elements of double minute chromosomes in human ovarian cells capable of enhancing gene expression. PLoS One (2012) 0.78
Association between sister chromatid exchange and double minute chromosomes in human tumor cells. Mol Cytogenet (2015) 0.75
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol (1997) 29.02
Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med (1979) 6.00
Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies. J Clin Oncol (2001) 5.17
A phase II trial of gemcitabine in patients with 5-FU-refractory pancreas cancer. Ann Oncol (1996) 4.07
Hypersensitivity reactions from taxol. J Clin Oncol (1990) 3.83
ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents. Nat Med (1997) 3.64
Clinical relevance of tumor cell ploidy and N-myc gene amplification in childhood neuroblastoma: a Pediatric Oncology Group study. J Clin Oncol (1991) 3.16
Quantitative analysis of MDR1 (multidrug resistance) gene expression in human tumors by polymerase chain reaction. Proc Natl Acad Sci U S A (1990) 3.03
An internal deletion within an 11p13 zinc finger gene contributes to the development of Wilms' tumor. Cell (1990) 3.02
Results of allogeneic bone marrow transplants for leukemia using donors other than HLA-identical siblings. J Clin Oncol (1997) 2.79
Pax-2 is a DNA-binding protein expressed in embryonic kidney and Wilms tumor. Proc Natl Acad Sci U S A (1992) 2.42
Chromosome translocation in peripheral neuroepithelioma. N Engl J Med (1984) 2.22
Characterization of human proliferative T cell responses to adenovirus. J Infect Dis (1995) 2.15
Ras protein farnesyltransferase: A strategic target for anticancer therapeutic development. J Clin Oncol (1999) 2.00
Toxic effects of cis-dichlorodiammineplatinum(II) in man. Cancer Treat Rep (1980) 1.99
There is no role for hyperfractionated radiotherapy in the management of children with newly diagnosed diffuse intrinsic brainstem tumors: results of a Pediatric Oncology Group phase III trial comparing conventional vs. hyperfractionated radiotherapy. Int J Radiat Oncol Biol Phys (1999) 1.96
Association between human tumor colony-forming assay results and response of an individual patient's tumor to chemotherapy. Am J Med (1981) 1.92
T-lymphocyte subpopulations in patients with classic hemophilia treated with cryoprecipitate and lyophilized concentrates. N Engl J Med (1983) 1.91
Editors have ethical responsibilities, too. N Engl J Med (1984) 1.91
Amplification of the gli gene in childhood sarcomas. Cancer Res (1989) 1.84
Double minute chromosomes can be produced from precursors derived from a chromosomal deletion. Mol Cell Biol (1988) 1.81
Randomized comparison of cisplatin/vincristine/fluorouracil and cisplatin/continuous infusion doxorubicin for treatment of pediatric hepatoblastoma: A report from the Children's Cancer Group and the Pediatric Oncology Group. J Clin Oncol (2000) 1.70
G-quadruplexes as targets for drug design. Pharmacol Ther (2000) 1.63
Effects of cationic porphyrins as G-quadruplex interactive agents in human tumor cells. Cancer Res (1999) 1.63
Isolation of transplantable erythroleukemia cells from mice infected with helper-independent Friend murine leukemia virus. Blood (1981) 1.61
A phase I study of Onyx-015, an E1B attenuated adenovirus, administered intratumorally to patients with recurrent head and neck cancer. Clin Cancer Res (2000) 1.59
Preirradiation chemotherapy with carboplatin and etoposide in newly diagnosed embryonal pediatric CNS tumors. J Clin Oncol (1995) 1.58
Characterization of an episome produced in hamster cells that amplify a transfected CAD gene at high frequency: functional evidence for a mammalian replication origin. Mol Cell Biol (1987) 1.58
Transforming growth factor beta: potential autocrine growth inhibitor of estrogen receptor-negative human breast cancer cells. Cancer Res (1988) 1.57
Phase I and pharmacologic study of the specific matrix metalloproteinase inhibitor BAY 12-9566 on a protracted oral daily dosing schedule in patients with solid malignancies. J Clin Oncol (2000) 1.57
Phase I and pharmacologic study of the tyrosine kinase inhibitor SU101 in patients with advanced solid tumors. J Clin Oncol (1999) 1.56
A comparison of clinical pharmacodynamics of different administration schedules of oral topotecan (Hycamtin) Clin Cancer Res (1999) 1.54
Unique expression of the human Evi-1 gene in an endometrial carcinoma cell line: sequence of cDNAs and structure of alternatively spliced transcripts. Oncogene (1990) 1.53
Etoposide, ifosfamide, and cisplatin therapy for refractory childhood solid tumors. Response and toxicity. Cancer (1995) 1.49
Diagnostic reliability of needle biopsy of the parietal pleura. A review of 272 biopsies. Am J Clin Pathol (1975) 1.48
Prospective clinical trial of a human tumor cloning system. Cancer Res (1983) 1.44
A phase I clinical and pharmacokinetic study of the angiogenesis inhibitor, tecogalan sodium. Ann Oncol (1996) 1.43
Daunomycin-induced cardiotoxicity in children and adults. A review of 110 cases. Am J Med (1977) 1.42
A multicenter, phase II trial of weekly irinotecan (CPT-11) in patients with previously treated colorectal carcinoma. Cancer (1999) 1.41
Phase II trial of irinotecan in patients with progressive or rapidly recurrent colorectal cancer. J Clin Oncol (1996) 1.41
A method for the evaluation of dose-toxicity relationships in clinical trials. Stat Med (1989) 1.39
Wilms' tumor: reduced-dose radiotherapy in advanced-stage Wilms' tumor with favorable histology. Int J Radiat Oncol Biol Phys (1990) 1.38
Is renal salvage feasible in unilateral Wilms' tumor? Proposed computed tomographic criteria and their relation to surgicopathologic findings. Am J Pediatr Hematol Oncol (1990) 1.38
A new method for studying splenic reticuloendothelial dysfunction in sickle cell disease patients and its clinical application: a brief report. Blood (1976) 1.38
Clinical correlates of MDR1 (P-glycoprotein) gene expression in ovarian and small-cell lung carcinomas. J Natl Cancer Inst (1992) 1.33
A phase I evaluation of multitargeted antifolate (MTA, LY231514), administered every 21 days, utilizing the modified continual reassessment method for dose escalation. Cancer Chemother Pharmacol (1999) 1.32
Engraftment and survival after unrelated-donor bone marrow transplantation: a report from the national marrow donor program. Blood (2000) 1.32
Consistent N-myc copy number in simultaneous or consecutive neuroblastoma samples from sixty individual patients. Cancer Res (1987) 1.31
Rhabdomyosarcoma complicating multiple neurofibromatosis. J Pediatr (1978) 1.26
Splice-site mutation of the p53 gene in a family with hereditary breast-ovarian cancer. Oncogene (1994) 1.25
Bone marrow transplantation from related donors other than HLA-identical siblings: effect of T cell depletion. Bone Marrow Transplant (1991) 1.23
Phase II trial of docetaxel in patients with advanced cutaneous malignant melanoma previously untreated with chemotherapy. J Clin Oncol (1995) 1.20
High-dose chemotherapy and autologous bone marrow rescue followed by interstitial and external-beam radiotherapy in newly diagnosed pediatric malignant gliomas. J Clin Oncol (1993) 1.19
Taxol: a new and effective anti-cancer drug. Anticancer Drugs (1991) 1.17
"Send this patient's tumor for culture and sensitivity". N Engl J Med (1983) 1.17
Characterization of cell lines derived from xenografts of childhood rhabdomyosarcoma. Cancer Res (1987) 1.17
Comparison of constitutional and tumor-associated 11;22 translocations: nonidentical breakpoints on chromosomes 11 and 22. Proc Natl Acad Sci U S A (1986) 1.16
Activity of topotecan, a new topoisomerase I inhibitor, against human tumor colony-forming units in vitro. J Natl Cancer Inst (1992) 1.16
The cardiotoxicity of anticancer agents. Semin Oncol (1982) 1.15
cis-Dichlorodiammineplatinum(II) for the treatment of advanced ovarian cancer. Cancer Treat Rep (1980) 1.15
Phase I clinical trial of gemcitabine given as an intravenous bolus on 5 consecutive days. Eur J Cancer (1994) 1.15
Alternative complement pathway activity in sera from patients with sickle cell disease. Clin Exp Immunol (1976) 1.15
Linkage of familial Wilms' tumor predisposition to chromosome 19 and a two-locus model for the etiology of familial tumors. Cancer Res (1998) 1.14
In vitro antitumor activity of the novel marine agent, ecteinascidin-743 (ET-743, NSC-648766) against human tumors explanted from patients. Ann Oncol (1998) 1.14
In vitro stem cell assay in head and neck squamous carcinoma. Am J Surg (1980) 1.14
Detection of the (11;22)(q24;q12) translocation of Ewing's sarcoma and peripheral neuroectodermal tumor by reverse transcription polymerase chain reaction. Am J Pathol (1993) 1.13
Teratoid Wilms' tumor: the St Jude experience. J Pediatr Surg (1988) 1.13
A bioavailability and pharmacokinetic study of oral and intravenous hydroxyurea. Blood (1998) 1.13
Phase I pharmacokinetic and pharmacodynamic study of the pan-PI3K/mTORC vascular targeted pro-drug SF1126 in patients with advanced solid tumours and B-cell malignancies. Eur J Cancer (2012) 1.11
Phase I and pharmacokinetic study of temozolomide on a daily-for-5-days schedule in patients with advanced solid malignancies. J Clin Oncol (1999) 1.11
Double minute chromosomes and homogeneously staining regions in tumors taken directly from patients versus in human tumor cell lines. Anticancer Drugs (1991) 1.11
Telomere-interactive agents affect proliferation rates and induce chromosomal destabilization in sea urchin embryos. Anticancer Drug Des (1999) 1.11
Human tumor cloning: feasibility and clinical correlations. Cancer Chemother Pharmacol (1981) 1.10
5-Azacytidine. A new anticancer drug with effectiveness in acute myelogenous leukemia. Ann Intern Med (1976) 1.10
Measure once or twice -- does it really matter? J Natl Cancer Inst (1999) 1.09
Mitoxantrone in epithelial carcinoma of the ovary. A Southwest Oncology Group study. Am J Clin Oncol (1984) 1.08
Successful allogeneic transplantation of T-cell-depleted bone marrow from closely HLA-matched unrelated donors. N Engl J Med (1990) 1.07
Detection of adenovirus DNA in peripheral blood mononuclear cells by polymerase chain reaction assay. J Med Virol (1997) 1.05
Investigation of taxol as a potential radiation sensitizer. Cancer (1993) 1.05
Mitoxantrone: a new anticancer drug with significant clinical activity. Ann Intern Med (1986) 1.04
Long-term results of selective renal shielding in patients undergoing total body irradiation in preparation for bone marrow transplantation. Bone Marrow Transplant (1997) 1.04
Primary extracranial rhabdoid tumors. Clinicopathologic features and response to ifosfamide. Cancer (1993) 1.04
Incidence of drug-related deaths secondary to high-dose methotrexate and citrovorum factor administration. Cancer Treat Rep (1977) 1.04
Antiproliferative effects of recombinant human bone morphogenetic protein-2 on human tumor colony-forming units. Anticancer Drugs (1998) 1.04
Medulloblastoma in very young children: outcome of definitive craniospinal irradiation following incomplete response to chemotherapy. J Clin Oncol (1994) 1.04
Phase I and pharmacokinetic study of paclitaxel in combination with biricodar, a novel agent that reverses multidrug resistance conferred by overexpression of both MDR1 and MRP. J Clin Oncol (1998) 1.04
Development of a new in vivo model for head and neck cancer. Otolaryngol Head Neck Surg (1990) 1.03
Model for estimation of clinically achievable plasma concentrations for investigational anticancer drugs in man. Cancer Treat Rep (1986) 1.03
Expression of insulin-like growth factor I, its binding proteins, and its receptor in ovarian cancer. Cancer Res (1991) 1.03
CC-1065 (NSC 298223), a most potent antitumor agent: kinetics of inhibition of growth, DNA synthesis, and cell survival. Cancer Res (1982) 1.03
Pyrazoloacridines, a new class of anticancer agents with selectivity against solid tumors in vitro. Cancer Res (1987) 1.03
Phase I and pharmacokinetic study of the oral fluoropyrimidine capecitabine in combination with paclitaxel in patients with advanced solid malignancies. J Clin Oncol (1999) 1.02
Preclinical antitumor activity of 6-hydroxymethylacylfulvene, a semisynthetic derivative of the mushroom toxin illudin S. Cancer Res (1997) 1.02
Prevention of docetaxel-induced erythrodysesthesia with local hypothermia. J Natl Cancer Inst (1994) 1.02
Use of an image analysis system to count colonies in stem cell assays of human tumors. Prog Clin Biol Res (1980) 1.02
Primary adrenal lymphoma. Cancer (1989) 1.02
A phase I clinical and pharmacokinetic study of the topoisomerase I inhibitor topotecan (SK&F 104864) given as an intravenous bolus every 21 days. Anticancer Drugs (1992) 1.01